|
Back to EZorb Newsletter Index |
|
In this issue:
1. Share Success: Letters From Readers Letter I: From Brenda B. I saw a comment in your EZorb newsletter Issue 353 from someone that credited EZorb with easing the pain from Polymyalgia Rheumatica. In Feb 2020 my DEXA scan showed I had severe Osteoporosis. After researching the drugs suggested to me I found your site and began taking EZorb. Then in Oct 2020 I was dx with PMR and gave in to prednisone to relieve the 24/7 pain. After almost 2 yrs I was able to wean off the prednisone and have been essentially pain free for 10 months, still taking the EZorb for my osteoporosis and hoping for a better score on my next DEXA scan in Feb 2024. Now I'm wondering if it was the EZorb that enabled me to get off the prednisone. What are your thoughts on that? Have others commented on a connection between EZorb and PMR? Medical Staff: Yes, EZorb has helped many people get off prednisone. And it’s proven to be effective against PMR. Letter II:
From Megan K. I've been taking Ezorb for quite a while, and it always helps a lot. I'll be honest the product is not cheap. There were several times I cut back on dosage, then was able to quit entirely for a few months. Then I started hurting again. I couldn't sleep. Neck and shoulders hurt, got those restless legs back again. So then I order more! Just want to learn to stay on track! From the Desk of EZorb Newsletter Editor:Our newsletter reaches over 230,000 subscribers worldwide. Success stories you shared in the past have made a great impact on many people's life. Please email your story to sharesuccess@ezorbonline.com or simply post it to Testimonial Submit Form. Your personal information will never be revealed to the public. 2. Research News: Night-time Apomorphine May Help Sleep for People with Parkinson’sA night-time only infusion of the dopamine agonist apomorphine could help to reduce sleep disturbances in patients with advanced Parkinson’s disease and moderate-to-severe insomnia, suggest the results of the APOMORPHEE trial. “Apomorphine improved insomnia as well as self-reported motor condition on morning awakening”, and overall the drug was well tolerated, report Valerie Cochen De Cock, from the University of Montpellier in France, and co-researchers in The Lancet Neurology. They therefore believe that night-time apomorphine “could be an effective option” for such patients, adding that “night-time administration could render apomorphine infusion more acceptable (compared with a 24-h infusion) because patients will not have to deal with the device-related constraints during the daytime.” For the double-blind, crossover trial, the investigators recruited 46 individuals aged 35-90 years (mean, 63.6 years) with Parkinson’s disease and a score of at least 15 points on the Insomnia Severity Index (ISI) from 11 centres in France. Participants were randomly assigned to receive apomorphine or placebo first for a 10-night titration phase followed by a 7-night fixed dose phase, a 3-night tapering phase and a 14-night washout period before switching. The patients took the assigned treatment at home with technical support from a healthcare professional and daily follow-up by telephone. The primary endpoint of change in Parkinson’s disease sleep scale (PDSS) score from baseline to the end of the study was significantly greater with night-time apomorphine than placebo, at an average of 15.18 versus 5.23 points, equating to a treatment effect of 9.95 points. Furthermore, the apomorphine treatment period was associated with significant improvements in insomnia as indicated by the ISI score (treatment effect, -2.23 points), self-estimated clinical global impression of sleep quality (1.40 points) as well as in the morning motor state (-0.57 points) compared with the placebo period. But there were no significant improvements with the use of night-time apomorphine in other efficacy measures including pain, fatigue, symptoms of sleep apnoea, presence and severity of restless legs syndrome and impulse control disorders. Study participants also underwent a night of audio and video polysomnography at the end of each treatment period, but the assessments did not show any clinically significant changes with apomorphine. The authors of a related commentary believe that this highlights “the possible limitations of polysomnography to assess sleep dysfunction in Parkinson’s disease.” They congratulate the study authors “for choosing a non-motor outcome measure (PDSS) as the primary endpoint, and for selecting pragmatic and broad eligibility criteria, thus ensuring robust external validity of their data.” K Ray Chaudhuri and Valentina Leta, both from King’s College London in the UK, believe that the APOMORPHEE results “could help clinicians to personalise their treatment strategy for patients with Parkinson’s disease, sleep dysfunction, and symptoms related to early-morning off periods.” But they stress the need for “long-term safety and efficacy data for night-time apomorphine infusion” in this setting. The current safety data encompassing the 54-day study period show that “the apomorphine infusion was well tolerated overall with no unexpected safety signals”, say Cochen De Cock and colleagues. Adverse events occurred in 54% of participants receiving apomorphine and 37% of those receiving placebo, a nonsignificant difference. However, the incidence of dizziness was significantly more common with apomorphine than placebo (15 vs 0%), and two participants discontinued the study during the apomorphine treatment phase due to dizziness and headache considered related to apomorphine. Original research was published in Lancet Neurol 2022; 21: 428–437. 3. Useful LinksEZorb - Frequently Asked Questions & Answers 4. What Are Others Saying About EZorb and Marvlix?EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families around the world. Click here to read what people say about EZorb and Marvlix. |
|
Back to EZorb Newsletter Index |